Jim Cramer’s Latest Lightning Round: 8 Stocks in Focus

6. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Number of Hedge Fund Holders: 21

A caller asked what Cramer’s thoughts on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) were and he said:

“Well, I’ll tell you… I’m reticent to put to, to really just to pull the trigger on Recursion because when they came on it was, it looked like at a good level and since then it’s just been disastrous. We’re going to have to hold off. I gotta meet them face to face and see what’s going on.”

Recursion Pharmaceuticals (NASDAQ:RXRX) is a biotechnology company in the clinical stage, aiming to transform drug discovery by incorporating advanced technology. It has several drug candidates undergoing clinical trials for a range of conditions. In November 2024, Cramer stated:

“I like the story at 10 and I have to tell you, you know what that makes me? That makes me wrong. I knew that Nvidia had a stake in it. They still do and it made me get excited about it… Then they did a secondary offering and it didn’t hold. Now I think at 5, it is worthwhile speculation.”